Olin Bio

 

  Operating income of 06,400 yuan，Net profit-19.876 million yuan，gross profit margin 99.40%

 

  Main Products: Human Vaccine Products

 

  Olin Biological Development、Innovative -driven biopharmaceutical companies in production and sales，A number of independent intellectual property rights including national 1 new drugs and qualification licenses such as drug production licenses，Provide high -quality vaccine products for domestic and foreign markets。

 

  The company develops business through the completed sales channel，The main business income source is product sales。Since the company’s first product has not yet obtained production approval，No sales income，The main expenditure is management expenses。Management costs occurred at 23.7159 million yuan in the previous period，Management costs The current period of 194.328 million yuan，reduced 18.06%compared with the same period last year。

 

  Olin Bio -A group C group C group meningitis vaccine officially carried out phase III clinical trials in May 2016，Class of new drugs reorganized Golden Poor Staphylococcal Vaccine in June 2016, which officially carried out phase I clinical trials。During this period，Company and the University of Girifis, Australia, conducting discussion on the cooperation between the Group A Streptococcus liposcopy vaccine project，and officially signed the "Intellectual Property Authorization License (Transfer Options) and Vaccine Cooperation Development stake betting appContracts" in July 2016，Obtain the exclusive vaccine in mainland China、Hong Kong、Commercial rights in Macau and Taiwan。

 

  Beno Medicine

 

  Business income is 223.826 million yuan，Net profit of 2.813 million yuan，gross profit margin 97.09%

 

  Main Products: Clinical Medicine R & D (antibacterial、Gastrointestinal category、Anti -tumor and other medicines)

 

  Beno Pharmaceutical is a high -tech enterprise mainly based on pre -clinical pharmaceutical research and development，Business belongs to pre -clinical research service industry in CRO。R & D project covers a wide range of fields，Including antibacterial、Gastrointestinal category、Anti -tumor、Circulation System Class、nervous system category、Urinary System、Mental disorder、Drugs such as respiratory system。

 

  Beno Pharmaceuticals through the transfer of clinical pharmaceutical research and development technical achievements，To obtain related technology transfer service fees。Company's business experience advantage、Platform advantages and brand advantages make the company have high profitability，At the same time, it is also guaranteed that the business model will have a high sustainability in the future。

 

  It is worth mentioning is，Beno Medicine established BE detection center，This center can develop the human biological equivalent test of drugs for self -developed projects，In the future，to open up new profit growth points。

 

  Feipeng Bio

 

  Business income 711.855 million yuan，Net profit of 37.406 million yuan，gross profit margin 95.33%

 

  Main products: antigen products、antibody products、diagnostic enzyme products

 

  Feipeng Bio is a family based on the in vitro diagnostic reagent industry，Development of the core raw materials of in vitro diagnostic reagents、Production and sales is the entry point，High -tech enterprises with the industry's industry chain global leading technology platform。

 

  In addition to providing customers with the core raw material products of in vitro diagnostic reagents，Relying on the technical platform accumulated in the product development process，Provide customers with professional in vitro diagnostic reagent comprehensive solutions，It mainly includes providing customers with personalized core raw materials custom development and comprehensive、Professional reagent development technology solution，The content covers Stake Sports Bettingthe optimization exploration of the kit solution system、Multiple services such as targeted exploration of raw materials and targeted adjustments of raw material treatment agents。

 

  In the first half of 2016，Philippine Biological Realization of operating income 7,11.855 million yuan，increased by 21.62%year -on -year，Mainly new products developed gradually pushed to the market，and the increase in sales of international markets。

 

  Realizing net profit 3,7.4062 million yuan，increased by 10.97%year -on -year，Net profit growth is less than the growth rate of operating income，Mainly increased sales investment in the international market，Personal expenses、Travel fee、Exhibition and advertising costs have increased significantly，Continue to increase R & D investment，Caused the expenses to increase significantly。

 

  gross profit margin is 95.33%，A slight increase year -on -year，Mainly the increase in product output，Unit product sharing fixed costs decrease，Promote the rising gross profit margin slightly。

 

  Ruiji Bio

 

  Business income 12.317 million yuan，Net profit of 3.590 million yuan，gross profit margin 94.21%

 

  Main Products: There are filter paper amniotic fluids、Burted surface amniotic fluid、Biological orthopedic amniotic fluid

 

  Ruiji Bio is mainly engaged in the development of bioline products、Manufacturing and sales，At present, the product is mainly used for ophthalmology、Orthopedics。The main customers are powerful medical device dealers distributed in various provinces and cities across the country and the famous three hospitals。

 

  In the first half of 2016，The establishment of a more effective sales network in Ruiji Bio，A large investment in the construction of sales channels，Breaking the previous regional agency system，Transfer to upgrade to terminal channel authorization system，Make the dealer more targeted、Competitive。In terms of marketing strategy，Continue to promote & ldquo; precision & rdquo; marketing strategy，Stable existing market，Expansion of the undeveloped market，Improve the share of corporate products in the domestic medical device market。

 

  The sales of Ruiji creatures biased towards bump surface amniotic fluid，Gradually transferred the high -precision product market from the low price market，Avoid malignant homogeneous competition，Therefore, the gross profit margin increased from 86%in the same period last year stake sports betting appto 94.2%，At the same time, due to the sales market of the second -generation bump surface amniotic fluid products，Realizing sales income of 12.3173 million yuan，increased by 152.07%year -on -year。

 

  Shi Mei Pharmaceutical

 

  Business income of 47.337 million yuan in net profit of 33,450,700 yuan gross profit margin 90.66%

 

  Main Products: Platinosulfonate Llysitatian flat tablets

 

  Shi Mei Pharmaceutical is a family focusing on the development of hand -based drugs、National High -tech Enterprise，Have a national innovation platform & mdash; & mdash; hand -based chemical drug manufacturing technology National local joint engineering research center，It is the leading company in the hand -pharmaceutical sub -industry。Except for drug production and sales，It also provides drug research and development technology achievement transformation services，formed & ldquo; Drug sales+technical achievements transformation service & rdquo; & ldquo; dual -core driver & rdquo; unique business model。

 

  Shi Mei Pharmaceuticals achieved operating income in the first half of the year 4,7.3374 million yuan，increased by 2.99%year -on -year。Among them: drug sales income 1,885.7 million yuan，decreased by 7.85%year -on -year，Technical achievements transformation service income 2,84.804 million yuan，increased by 11.69%year -on -year。The net profit attributable to shareholders is 3,34.507 million yuan，increased by 0.45%year -on -year，The main reason is the composition of multiple technical achievements transformation services，costs have increased from last year。

 

  In terms of gross profit margin，Shimei Pharmaceutical in the first half of the year is 90.66%，The gross profit margin of the same period last year was 94.42%，Where: the gross profit margin of drug sales is 86.77%，The gross profit margin of the same period last year was 89.05%，The main reason is that the sales unit price decreases slightly，Rising labor costs。Technical achievements conversion service sales gross margin 93.23%，The gross profit margin of the same period last year was 98.73%，The main reason is that the technical achievement conversion service is targeted at a single project transfer，The change of gross profit margin is incompletely comparable。

 

  垠 艺

 

  Business income of 57.7019 million yuan in net profit of 8.772 million yuan gross profit margin 90.15%

 

  Main Products: Drug coating coronary arterial metal My stake betting appstent system and balloon expansion duct

 

  Yiyi Bio is mainly engaged in the design of coronary arteries interventional medical equipment and congenital heart disease intervention in the medical device industry、R & D、Production and sales，Have the corresponding medical device production license and business license。

 

  Yiyi Bio achieved operating income of 57.019 million yuan in the first half of the year，increased by 11.27%year -on -year，The main reason is that the market propaganda is increased; net profit is 8.9736 million yuan，increased by 46.76%year -on -year，The main reason is the profit growth brought by income growth，Another income tax fee decreases。

 

  At the end of June this year，New Third Board layered plan is officially implemented，I have taken the first step to solve the problem of market liquidity，Attract more pharmaceutical companies & ldquo; enter & rdquo; New Third Board，I believe that more potential products will appear in the future。